Skip to content

Author

T. Mukohara

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Aug 2026

Primary Leiomyosarcoma of the Breast: A Case with Rapidly Progressive Clinical Course

Abstract Introduction Primary leiomyosarcoma (LMS) of the breast is an exceptionally rare mesenchymal malignancy that accounts for <0.0006% of all breast neoplasms. Owing to its rarity and the nonspecific nature of conventional imaging, achieving an accurate preoperative diagnosis is often difficult. Case Presentation...

Asako Yamamoto, R. Watanuki, Junko Kikuchi et al. · 0 citations
Clinical trial Open access Sep 2026

E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114

The results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study.

Hiroshi Ishiguro, Y. Miyoshi, H. Yasojima et al. · 0 citations
Open access Sep 2026

Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

OBJECTIVE Human epidermal growth factor receptor (HER) 3, encoded by the ERBB3 gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and ERBB3 messenger...

K. Yokosu, Riu Yamashita, Satoshi Fujii et al. · 0 citations
Open access Sep 2026

Potential of β-catenin inhibitors as a novel therapeutic strategy for PIK3CA/CTNNB1 double-mutant endometrial cancer

Endometrial cancer (EC) is one of the most prevalent gynecological malignancies. EC is characterized by limited therapeutic options and a substantial unmet medical need, particularly in advanced or metastatic stages. Although a high prevalence of concurrent PIK3CA and CTNNB1 mutations has been reported in patie...

Takehiro Nakao, R. Kamata, Hitoshi Saito et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.